1. Scrip
  2. >>Business

Merck KGaA’s Dealmaking Slows

 
• By Elizabeth Cairns

And the deals it has signed recently will not begin to pay off for some years to come.    

Merck KGaA Darmstadt

Back in March when it unveiled its full-year 2023, Merck KGaA made it clear that it was on the lookout for licensing deals. (Also see "Merck KGaA Wants Your Drugs" - Scrip, 7 March, 2024.) Today, discussing its first-quarter results, the company said this approach was beginning to pay off.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies

 
• By Mandy Jackson

Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.